Henry Schein (HSIC)
(Delayed Data from NSDQ)
$72.33 USD
+1.96 (2.79%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $72.35 +0.02 (0.03%) 4:56 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.33 USD
+1.96 (2.79%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $72.35 +0.02 (0.03%) 4:56 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Align Technology (ALGN) Debuts Latest Feature for ClinCheck
by Zacks Equity Research
Align Technology's (ALGN) CBCT integration feature for ClinCheck will enable doctors to treat a broader range of cases with the Invisalign clear aligners.
Henry Schein (HSIC) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Buy McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Is Henry Schein (HSIC) a Suitable Pick for Value Investors?
by Zacks Equity Research
Is Henry Schein (HSIC) a great pick from the value investor's perspective right now? Read on to know more.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from its strong international presence and solid DaVita Kidney Care business. However, integration risks are a woe.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
PerkinElmer's (PKI) Latest Launch to Boost Food Analysis Suite
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.
Exact Sciences (EXAS) Cologuard Sales Up but Costs Rise
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.
Boston Scientific (BSX) Hurt by Price and Volume Issues
by Zacks Equity Research
The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, contraction in gross margin is a woe.
DexCom (DXCM) to Boost Diabetes Management With New Approval
by Zacks Equity Research
DexCom's (DXCM) G7 CGM System receives CE Mark that can help people with diabetes in Europe, including pregnant women.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.
Here's Why You Should Hold on to Medtronic (MDT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.
Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales
by Zacks Equity Research
Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Baxter (BAX) to Enhance Its Portfolio With Latest Partnership
by Zacks Equity Research
Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.
Here's Why You Should Hold NextGen (NXGN) Stock For Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
Dexcom (DXCM) G6 CGM System Gets Public Coverage From Ontario
by Zacks Equity Research
Dexcom's (DXCM) G6 CGM System can help people with type 1 diabetes over two years of age through the coverage announced by the Ontario government.
Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm
by Zacks Equity Research
WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.
Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.
Here's Why You Should Retain Illumina (ILMN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.